Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06349642 · ClinicalTrials.gov registry record
Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
A clinical trial of Metastatic Lung Non-Small Cell Carcinoma and Metastatic Colorectal Carcinoma, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- 324
- Enrollment target
- 3
- Study locations
NCT06349642 is a study of Metastatic Lung Non-Small Cell Carcinoma and Metastatic Colorectal Carcinoma that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 324 participants, above the 69-participant average among 39 other Metastatic Lung Non-Small Cell Carcinoma trials with a reported enrollment target (370% higher). The trial reports 3 study locations across 3 states.
The verdict
NCT06349642, a study of Metastatic Lung Non-Small Cell Carcinoma and Metastatic Colorectal Carcinoma, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- 324 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study is being done to collect tissue samples to test how accurately a tumor response platform, Elephas, can predict clinical response across multiple types of immunotherapies, chemoimmunotherapy and tumor types.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Tissue Collection
Study Locations (3)
Arizona
- Mayo Clinic in Arizona - Phoenix
Florida
- Mayo Clinic in Florida - Jacksonville
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 324 participants |
| Start Date | 2024-04-24 |
| Est. Completion | 2027-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06349642
The ClinicalTrials.gov registry entry for NCT06349642 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 324 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 69-participant average among 39 other Metastatic Lung Non-Small Cell Carcinoma trials with a reported enrollment target (370% higher). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Metastatic Lung Non-Small Cell Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Biospecimen Collection is the first listed.
NCT06349642 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Arizona, Florida, Minnesota.
Frequently Asked Questions
What is clinical trial NCT06349642 about?
NCT06349642 is a clinical study titled "Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform". This study is being done to collect tissue samples to test how accurately a tumor response platform, Elephas, can predict clinical response across multiple types of immunotherapies, chemoimmunotherapy and tumor types.
What is the current status of trial NCT06349642?
This trial is currently recruiting. The enrollment target is 324 participants. The study started on 2024-04-24. Estimated completion is 2027-05.
What conditions does trial NCT06349642 study?
This clinical trial studies the following conditions: Metastatic Lung Non-Small Cell Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Early Stage Triple-Negative Breast Carcinoma.
What interventions are being tested in trial NCT06349642?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Tissue Collection (PROCEDURE).
Who is sponsoring clinical trial NCT06349642?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06349642 being conducted?
This trial has 3 study locations across Arizona, Florida, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Lung Non-Small Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
PET/CT Changes During Chemoimmunotherapy and Radiation Therapy in Patients With Stage IV Non-small Cell Lung Cancer
RECRUITING · NA
-
PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy
RECRUITING · Phase 2
-
Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
RECRUITING · Phase 1
Explore more on PlainTrial
Metastatic Lung Non-Small Cell Carcinoma
All registered trials for this condition
Metastatic Colorectal Carcinoma
All registered trials for this condition
Arizona
All trials with a study site in Arizona
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.